Molecular Targeted Therapies for Head and Neck Cancer: A New Era in DNA-based Therapeutics
ISSN: 2161-119X
Otolaryngology: Open Access

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
  • Editorial   
  • Otolaryngology 2012, Vol 2(4): e105
  • DOI: 10.4172/2161-119X.1000e105

Molecular Targeted Therapies for Head and Neck Cancer: A New Era in DNA-based Therapeutics

Sufi Mary Thomas*
Departments of Otolaryngology and Pharmacology and Chemical Biology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, USA
*Corresponding Author: Dr. Sufi Mary Thomas, 200 Lothrop Street, W947, Pittsburgh, PA, USA, Tel: (412) 383-5403, Email: [email protected]

Received Date: Aug 22, 2012 / Accepted Date: Aug 23, 2012 / Published Date: Aug 25, 2012

Over the past decade, the field of cancer therapeutics has slowly moved towards selective molecular targeting of oncogene addicted tumors. Inhibition of molecules overexpressed in or critical for vital mechanisms in cancer cells should theoretically induce selective tumor cell death. Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer world-wide. The front runner in molecular targets for HNSCC has been the Epidermal Growth Factor Receptor (EGFR), although other targets are also being developed in the light of low clinical outcomes using single agent EGFR inhibitors including cetuximab and erlotinib.

Even as the search for EGFR inhibitors with higher efficacy continues, DNA-based approaches including EGFR antisense gene therapy are demonstrating promising results in clinical trials. A plasmid DNA expressing antisense EGFR injected intratumorally in HNSCC patients in a phase 1 setting demonstrated a clinical response in 29% of patients with reduction in tumor EGFR levels post treatment [1]. The treatment was well tolerated by patients. Other molecules downstream of receptor tyrosine kinases that may prove useful as targets include PLCγ-1, phosphoinositol-3 kinase (PI-3K), Src family kinases, mammalian target of rapamycin (mTOR) and signal transducers and activators of transcription (STATs). Among the STATs, STAT3 in particular is reported to be upregulated and constitutively activated by EGFR in HNSCC primary tumors. In a highly innovative study, a double stranded DNA based decoy approach targeting STAT3 was tested in a phase 0 clinical setting [2]. Intratumoral administration of the STAT3 decoy resulted in a reduction of target gene expression indicating that the decoy was effective in blocking STAT3 function within the tumor cells. DNA-based agents are also attractive as vaccines. A DNA construct encoding human papilloma virus (HPV) E7 antigen is being tested for efficacy in enhancing T-cell-mediated antitumor immune responses in HPV-related HNSCC tumors ( identifier NCT01493154).

Critical aspects in the development of DNA-based molecular inhibitors, is to achieve serum stability and tumor-uptake of the agent, identify the best suited patient population and to have measurable responses to therapy. Ideally patient screening would involve confirmation of the oncogenic dependence of the individual’s tumor to the particular molecular target being tested. Response to therapy can be measured at the macroscopic level, wherein the tumor size and degree of cellular differentiation are examined or at the molecular level, where levels of target biomarkers are quantified. Although there have been just a handful of studies using DNA-based agents for the treatment of HNSCC, the results have been promising enough to encourage the development of DNA-based agents that can be systemically delivered to specifically target HNSCC tumors.


Citation: Thomas SM (2012) Molecular Targeted Therapies for Head and Neck Cancer: A New Era in DNA-based Therapeutics. Otolaryngology 2:e105. Doi: 10.4172/2161-119X.1000e105

Copyright: © 2012 Thomas SM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences

7th European Otolaryngology-ENT Surgery Conference

Vienna, Austria
Article Usage
  • Total views: 12376
  • [From(publication date): 12-2012 - Sep 20, 2021]
  • Breakdown by view type
  • HTML page views: 8449
  • PDF downloads: 3927
Share This Article